Ischaemic heart disease as the underlying cause of heart failure is associated with a worse prognosis and alters the efficacy of standard medical therapies.
Highlights the need for randomized controlled trials to establish evidence-based management for coronary disease in patients with heart failure.
Ischaemic heart disease is the most common underlying cause of heart failure in industrialised countries. Its manifestations are protean with myocardial infarction being only one important facet. The prognosis of patients with heart failure due to ischaemic heart disease also appears to be worse than that associated with many other aetiologies. The presence of ischaemic heart disease may influence both the efficacy and choice of treatment. Agents such as digoxin and amlodipine appear less effective in patients with ischaemic heart disease while ACE inhibitors and beta-blockers appear as or more effective in patients with ischaemic heart disease. Many have expressed an opinion about how coronary disease should be managed in the patient with heart failure supported by little or no evidence. There are major theoretical and practical concerns about the use of anti-coagulant, anti-platelet and statin therapy in patients with heart failure as well as major theoretical benefits. Only randomised controlled trials will resolve these issues. The same may be said of revascularisation. Fortunately trials addressing all these areas are under way. This should put the management of coronary disease in patients with heart failure on a firm evidence-based footing.
Cleland et al. (Tue,) conducted a review in Heart failure due to ischaemic heart disease. Ischaemic heart disease as the underlying cause of heart failure is associated with a worse prognosis and alters the efficacy of standard medical therapies.